OncoMatch/Clinical Trials/NCT06905509
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Is NCT06905509 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for recurrent diffuse large b-cell lymphoma.
Treatment: Carboplatin · Cytarabine · Dexamethasone · Epcoritamab · Etoposide Phosphate · Gemcitabine · Ifosfamide · Oxaliplatin · Rituximab — This phase II trial tests how well epcoritamab in combination with standard of care (SOC) platinum-based chemotherapy (rituximab, ifosfamide, carboplatin, etoposide \[RICE\], rituximab, cytarabine, dexamethasone, oxaliplatin or carboplatin RDHAP/X\] or gemcitabine and oxaliplatin \[Gem/Ox\]) and autologous hematopoietic cell transplant (HCT) works in treating patients with large B-cell lymphoma (LBCL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Epcoritamab, a type of bispecific T-cell engager, binds to a protein called CD3, which is found on T cells (a type of white blood cell). It also binds to a protein called CD20, which is found on B cells (another type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells and some types of cancer cells. This may help the immune system kill cancer cells. Chemotherapy drugs, such as ifosfamide, etoposide phosphate, cytarabine, and gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. An autologous HCT is a procedure in which blood-forming stem cells (cells from which all blood cells develop) are removed, stored, and later given back to the same person. Giving epcoritamab in combination with SOC platinum-based chemotherapy, such as RICE, RDHAP/X and Gem/Ox, and autologous HCT may kill more cancer cells in patients with relapsed or refractory LBCL.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD20 overexpression (CD20+)
Histological confirmed CD20+ relapsed/ refractory large cell lymphoma
Allowed: MYC rearrangement
with concurrent MYC and BCL2 rearrangements
Allowed: BCL2 rearrangement
with concurrent MYC and BCL2 rearrangements
Allowed: BCL6 rearrangement
with MYC and BCL6 rearrangements
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy — large cell lymphoma
Have received 1 or more prior lines of systemic therapy for the treatment of large cell lymphoma
Cannot have received: bispecific T-cell engager
Previous treatment with any bispecific T-cell engager with or without chemotherapy
Cannot have received: allogeneic hematopoietic stem cell transplantation
Participant received any prior allogeneic hematopoietic stem cell transplantation (HSCT)
Cannot have received: solid organ transplantation
Participant received any prior ... solid organ transplantation
Lab requirements
Blood counts
Hemoglobin ≥ 8.0 g/dL; Absolute neutrophil count ≥ 1000/uL; Platelet count ≥ 75,000/uL or ≥ 50,000/uL if bone marrow involvement or splenomegaly; prothrombin time (PT)/international normalized ratio (INR)/activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN
Kidney function
Creatinine clearance (CrCl) ≥ 45 mL/min (Cockcroft-Gault)
Liver function
Serum alanine aminotransferase (ALT) ≤ 3 x ULN; Serum aspartate aminotransferase (AST) ≤ 3 x ULN; Bilirubin ≤ 1.5 x ULN unless due to Gilbert's syndrome or controlled autoimmune hemolytic anemia (not requiring immunosuppressive other than ≤ 20 mg of prednisolone daily)
Cardiac function
No unstable or uncontrolled cardiac disease; No myocardial infarction, intracranial bleed, or stroke within the past 6 months; Screening 12-lead ECG QTcF ≤ 480 msec (unless left bundle branch block); Cardiology consult required if history of cardiovascular disease within 60 days prior to enrollment; Age ≥ 75 and 2 or more active grade ≥ 2 cardiovascular conditions excluded
Creatinine clearance (CrCl) ≥ 45 mL/min (Cockcroft-Gault); Serum alanine aminotransferase (ALT) ≤ 3 x ULN; Serum aspartate aminotransferase (AST) ≤ 3 x ULN; Bilirubin ≤ 1.5 x ULN unless due to Gilbert's syndrome or controlled autoimmune hemolytic anemia (not requiring immunosuppressive other than ≤ 20 mg of prednisolone daily); Hemoglobin ≥ 8.0 g/dL; Absolute neutrophil count ≥ 1000/uL; Platelet count ≥ 75,000/uL or ≥ 50,000/uL if bone marrow involvement or splenomegaly; prothrombin time (PT)/international normalized ratio (INR)/activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN; Cardiac criteria as detailed in exclusion criteria
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California Davis Comprehensive Cancer Center · Sacramento, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify